Eye tracking as a digital biomarker in neurodegenerative diseases
Journal of Neurology · 2026-02 · 273 (2)
DOI: 10.1007/s00415-026-13666-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurology, online erschienen am 10.02.2026. Verfasst von Paul S Giacomini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Neurological Institute, Multiple Sclerosis Clinic, Montreal, QC, Canada. paul.giacomini@innodemneurosciences.com. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Eye-Tracking Technology. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Canada.
Abstract (Originalsprache)
Oculomotor abnormalities are a common finding in neurodegenerative diseases due to degeneration of neural pathways and brain regions involved in controlling eye movements. Pathological changes to the dorsolateral prefrontal cortex, basal ganglia, superior colliculus and cerebellum produce subtle changes in eye-movement metrics that may not be detected by clinical examination. The present review addresses the potential use of eye-movement biomarkers in neurodegenerative conditions such as multiple sclerosis, Parkinson's disease, Alzheimer's disease and other dementias, and amyotrophic lateral sclerosis. Eye-movement metrics such as saccades, anti-saccades, fixation and smooth pursuit are prognostic of disease progression, can differentiate pathologic subtypes as an aid to diagnosis, and enable clinicians to evaluate early worsening of motor and cognitive function. The cost of medical technologies limits their optimal use and accessibility in clinical practice. The shortage of subspecialist neurologists further limits access to care. New eye-tracking technologies incorporated into widely-accessible digital devices such as smart phones and tablets now permit detailed assessments with minimal equipment requirements, providing an important non-invasive and potentially cost-effective method for patient evaluation in routine clinical practice and as an aid to treatment decision-making. Digital biomarkers can be readily employed by healthcare professionals such as family physicians, nurses and pharmacists to bridge the care gaps, potentially providing them with powerful tools that can be broadly adopted to improve the delivery of care to patients with neurodegenerative conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montreal Neurological Institute, Multiple Sclerosis Clinic, Montreal, QC, Canada. paul.giacomini@innodemneurosciences.com.
- Innodem Neurosciences, Montreal, QC, Canada. paul.giacomini@innodemneurosciences.com.
- Innodem Neurosciences, Montreal, QC, Canada.
- Division of Neurology, University of British Columbia, Vancouver, BC, Canada.
- BARLO MS Centre, St. Michael's Hospital, Toronto, ON, Canada.
- Department of Neurology, Centre de Recherche, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.
Förderung
- Novartis Pharmaceuticals Canada
Zitieren
APA
Giacomini, P. S., Voss, P., Devonshire, V., Schneider, R., Macaron, G., Hussein, S., Blanchette, F., & de Villers-Sidani, É. (2026). Eye tracking as a digital biomarker in neurodegenerative diseases. Journal of Neurology, 273(2). https://doi.org/10.1007/s00415-026-13666-8
Vancouver
Giacomini PS, Voss P, Devonshire V, Schneider R, Macaron G, Hussein S, et al. Eye tracking as a digital biomarker in neurodegenerative diseases. Journal of Neurology. 2026;273(2). doi:10.1007/s00415-026-13666-8
BibTeX
@article{Giacomini2026,
author = {Giacomini, Paul S and Voss, Patrice and Devonshire, Virginia and Schneider, Raphael and Macaron, Gabrielle and Hussein, Shamiza and Blanchette, François and de Villers-Sidani, Étienne},
title = {Eye tracking as a digital biomarker in neurodegenerative diseases},
journal = {Journal of Neurology},
year = {2026},
volume = {273},
number = {2},
doi = {10.1007/s00415-026-13666-8}
}
EUVIMED